Dynacure’s quick transfer

Born via Kurma’s industry-tied tech transfer model, Dynacure heads for the clinic

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also the biggest announced yet by a start-up formed via Kurma Partners S.A.’s company creation model, which the French firm revealed in late 2016.

Andera Partners (formerly Edmond de

Read the full 620 word article

User Sign In